Document is current
Any future updates will be listed below
-
Authors
Domingo, Nadia D.
Solomon, Olivia D.
Villarreal, Paula
Aussenac, Florentin
Vanegas, Difernando
Endrino, Mark Joseph
Mendiola, Andrew S.
Puebla-Clark, Lucinda
Gbedande, Komi
Cardona, Astrid E.
Akassoglou, Katerina
Flick, Matthew J.
Vargas, Gracie
Stephens, Robin
-
Funding
Funding for this research was provided by:
NIH (R01NS106597)
NIH (R01NS106597)
- License Information
-
More Information
Article History
Received: 23 January 2026
Accepted: 12 July 2026
First Online: 24 July 2026
Declarations
Ethics approval and consent to participate: All procedures were approved on IACUC protocols UTMB (1904044) and RNJMS(202200006).
Consent for publication: Not applicable.
Competing interests: Katerina Akassoglou is the scientific founder, shareholder and advisor of Therini Bio and Akodio Therapeutics, and has served as a consultant for F. Hoffman-La Roche, Sanofi, and the Foundation for a Better World. Her interests are managed in accordance with Gladstone’s Institute conflict of interest policy. All other authors declare no competing interests.
